NEW BRUNSWICK, N.J.,
May 15, 2019 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) will host a meeting
today with industry analysts to review the strategy of its Janssen
Pharmaceutical Companies to deliver above-market, compound annual
growth through 2023. The company will also discuss its progress
across its six therapeutic areas, pipeline developments and capital
allocation framework.
Chairman and Chief Executive Officer Alex Gorsky and members of the Johnson &
Johnson leadership team, along with leaders of each of the
company's six therapeutic areas, including Immunology, Infectious
Diseases & Vaccines, Neuroscience, Cardiovascular &
Metabolism, Oncology and Pulmonary Hypertension, will provide a
detailed overview of the company's strategy to continue to drive a
robust pipeline of innovative medicines to generate near- and
long-term, volume-driven growth.
"Our pharmaceutical organization has created breakthrough
medicines to address some of society's greatest unmet medical
needs, resulting in meaningful outcomes and benefits to patients,"
said Mr. Gorsky. "That progress must continue as we consider the
future shape of healthcare. Greater transparency is already
empowering families, leaders of healthcare systems and insurers to
make informed choices. Our broad base is well-positioned to
continue delivering value creating innovations that will improve
outcomes."
At today's meeting, Johnson & Johnson will outline its key
drivers to deliver above-market growth at Janssen. This strategy
includes:
Maximizing the clinical potential of the company's
industry-leading portfolio with new indications, patient
populations and lines of therapy. A well-established industry
leader in R&D productivity, Janssen has earned major-market
regulatory approvals for 18 new products since 2011 spanning the
company's diverse portfolio across six therapeutic areas. Janssen
anticipates filing for regulatory approval of more than 40 line
extensions through 2023 to reach additional patients with unmet
medical needs.
Delivering on the pipeline with new, differentiated
medicines, with at least 10 NME filings and/or launches anticipated
through 2023. In 2019 to date, Janssen has gained U.S.
regulatory approvals for two first-in-class molecular entities,
SPRAVATO (esketamine) nasal spray for treatment-resistant
depression in adults and BALVERSA (erdaftinib) for the treatment of
adults with bladder cancer that has spread or cannot be removed
surgically. Additional medicines will be discussed that have the
potential to file or launch by 2023, including four that are new to
the pipeline, as well as advanced therapeutic modalities such as
gene therapy and RNA therapeutics.
Forging new approaches to discovery, development and delivery
of the company's transformational medicines. Janssen has an
evolving and differentiated R&D strategy that embraces both
disease areas and biological pathways, as well as new technologies
such as cell and gene therapy and broad-based application of data
science. Together with strong partnerships, this strategy will help
Janssen discover, develop and deliver the next wave of
transformational medicines.
Investing in innovation will continue to be a key pillar of
Johnson & Johnson's disciplined capital allocation
strategy. The company is also committed to delivering a
competitive and increasing dividend, having paid $9.5 billion in dividends to shareholders in
2018, and will continue to deploy capital to value-creating
acquisitions with more than $5 billion
dollars invested in acquisitions across the company in
recent months. Additionally, Johnson & Johnson is focused on
returning capital to shareholders through share repurchases and has
completed more than one-third of its $5
billion authorization announced last year as of March 2019. Together with its significant free
cash flow and strong balance sheet, the company intends to execute
all levers of its capital allocation strategy to fund future growth
opportunities while providing attractive returns to
shareholders.
About Today's Meeting
The meeting will be webcast
starting at 8:30 a.m. EDT today and
can be accessed along with full copies of the presentations and
speaker biographies via the Johnson & Johnson Investor
Relations website: www.investor.jnj.com. A replay will be available
shortly after the live webcast. Stay up to date on the day's
activity with Twitter by following @JNJNews and @JanssenGlobal.
About Johnson & Johnson
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the company to successfully
execute strategic plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or
within the supply chain; product efficacy or safety concerns
resulting in product recalls or regulatory action; significant
adverse litigation or government action, including related to
product liability claims; changes to applicable laws and
regulations, including tax laws and global health care reforms;
trends toward health care cost containment; changes in behavior and
spending patterns of purchasers of health care products and
services; financial instability of international economies and
legal systems and sovereign risk; increased scrutiny of the health
care industry by government agencies. A further list and
descriptions of these risks, uncertainties and other factors can be
found in Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended December 30, 2018,
including in the sections captioned "Cautionary Note Regarding
Forward-Looking Statements" and "Item 1A. Risk Factors," in the
company's most recently filed Quarterly Report on Form 10-Q and the
company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as
of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-outlines-strategy-to-deliver-above-market-growth-at-2019-pharmaceutical-business-review-300850399.html
SOURCE Johnson & Johnson